Posters

Relationship between subfoveal choroidal thickness and axial length and age in eyes with age-related macular degeneration after phacoemulsification

Poster Details

First Author: G.Gudauskiene LITHUANIA

Co Author(s): I. Povilaityte   D. Zaliuniene                 

Abstract Details

Purpose:

To evaluate the correlation between the subfoveal choroidal thickness (SFCT) changes measured by swept-source optical coherence tomography (SS-OCT) and axial length and age in patients with age-related macular degeneration (AMD).

Setting:

A prospective clinical study was performed at the Department of Ophthalmology of the Hospital of Lithuanian University of Health Sciences, Kaunas Clinics.

Methods:

16 eyes of 16 patients (mean age 73.28±6.059 years) with senile cataract and AMD received uncomplicated phacoemulsification and intraocular lens implantation. SFCT measurements were performed preoperatively (P), 1 month (M1) and 3 months (M3) after the surgery using 1050 nm DRI Triton SS-OCT (Topcon, Tokyo, Japan) at the same time 1-2 PM. The SFCT in the central ring was automatically calculated using ETDRS grid. Axial length (AL) was measured using Aladdin optical biometer based on optical low-coherence interferometry (Topcon, Tokyo, Japan).

Results:

8 (32%) men and 17 (68%) women were analysed (p=0.072). The mean M1/P SFCT difference was -2.33±22.62 µm (p=0.279). The mean M3/P SFCT difference was 12.45±28.32 µm (p=0.103). P, M1 and M3 SFCT separately correlated with AL (p=0.005, r=-0.548; p=0.012, r=-0.535; p=0.001, r=-0.762, respectively).

Conclusions:

There was a significant correlation between separate (P/ M1/ M3) SFCT measurements and AL in AMD patients and no correlation with age. There was no statistically significant correlation between SFCT change and AL and age in our study. Further investigations should be continued to confirm and better clarify our findings.

Financial Disclosure:

... gains financially from competing product or procedure, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... receives non-monetary benefits from a company producing, developing or supplying the product or procedure presented, ... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... is employed by a competing company, ... has significant investment interest in a company producing, developing or supplying product or procedure presented